ICYMI the @pacibio poster at #AACR17 looking at low-freq somatic variant detection using CCS on Sequel https://t.co/WZMSxw3PUW and @SeraCare
1:07pm April 5th 2017 via Hootsuite
ICYMI - Quest Diagnostics poster at #AACR17 https://t.co/aRpVj1vmhD using @SeraCare reference materials for solid tumor
1:04pm April 5th 2017 via Hootsuite
Davidson: Tomasetti's work may be a guiding principle; possible new hallmarks include non-mut epigenetics, microbiome as 'enabling' #AACR17
1:02pm April 5th 2017 via Hootsuite
Davidson: Precancer ref just published https://t.co/bNTAnSB4s1 #AACR17
1:01pm April 5th 2017 via Hootsuite
Davidson: Pre-Cancer Genome Atlas? '17 JAMA https://t.co/xBVtUF7mhN county-by-county measure of cancer incidence #AACR17
1:00pm April 5th 2017 via Hootsuite
Nancy Davidson (Univ WA) Early detection and prevention research #AACR17 Starts with acknowledgements.
12:59pm April 5th 2017 via Hootsuite
@niazafghan Here's the link: https://t.co/bz5NaSkDBn
12:58pm April 5th 2017 via Hootsuite in reply to niazafghan
@niazafghan Hi - not sure if you read my blog at https://t.co/yXJMjujFNx - it's for targeted, but pretty exciting… https://t.co/pdF2j7wKcZ
12:57pm April 5th 2017 via Hootsuite in reply to niazafghan
Jaffee: Rational combinations of Rx, leading to improved response rates. #AACR17
12:56pm April 5th 2017 via Hootsuite
Jaffee: Conclude a broadening of tumor types for IO, targeted Rx. Basic discoveries now translating into real benefit #AACR17
Jaffee: Advances in use of PARPi; PI3Ki (BYL719) and Olaparib in Ov ca, waterfall shows sig partial responders #AACR17
12:55pm April 5th 2017 via Hootsuite
Jaffee: Ph II SUMMIT study for pan-HER mutated cancers (multiple types) #AACR17
12:53pm April 5th 2017 via Hootsuite
Jaffee: Advances in HER2 targeted Rx: Lapatinib + traztuzumab in HER2+ KRAS WT mCRC, met primary endpt #AACR17
12:52pm April 5th 2017 via Hootsuite
Jaffee: Ph 2 of indoximod + pembrolizumab for adv melanoma: ORR 59% #AACR17
12:49pm April 5th 2017 via Hootsuite
Jaffee: Ph Ia for mTNBC w/atelzolizumab, responders: 100% alive after 1y, 38% for nonresp. Correlated with immune response #AACR17
12:48pm April 5th 2017 via Hootsuite
Jaffee: (That was for single nivolumab). OS for nivo/ipi in melanoma. Merkel Cell Carcinoma (MCC), Ph 1/2 ORR was 64% #AACR17
12:45pm April 5th 2017 via Hootsuite
Elizabeth Jaffee (Johns Hopkins MD): Therapeutics #AACR17 Long-term OS data from PD-1 checkpoint trials; 5-y OS was 16%, historical 4%
12:44pm April 5th 2017 via Hootsuite
Polyak: May be able to modulate fitness effects of cancer-assoc'd mutations by manipulating the microenvironment #AACR17
12:41pm April 5th 2017 via Hootsuite
Polyak: Cancer and luck: an adaptive landscape, where aging/damage alters this. Thus looking beyond mutations: context-dep selection #AACR17
12:40pm April 5th 2017 via Hootsuite
Polyak: First dual CD19/CD22 bispecific CART should decrease resistance due to antigen loss #AACR17
12:38pm April 5th 2017 via Hootsuite
Polyak: First report of activation of tumor neoantigen-spec T-cells in solid cancer w/personalized peptide vaccine from WES analysis #AACR17
Polyak: Microbiome and anti-tumor immunity: renal ca pts on antibiotics have lower anti-PD-1 response. #AACR17
12:37pm April 5th 2017 via Hootsuite
Polyak: Human error rate is constant (about 4%), Google data indicating machine learning rate is decreasing to be better now #AACR17
12:35pm April 5th 2017 via Hootsuite
Polyak: AI/Machine learning - 2.5 Exabytes of data is produced every day. Pathology is 'critical for precision medicine' #AACR17
12:34pm April 5th 2017 via Hootsuite
Polyak: Getz (Broad) after >2,700 'still more whole genomes are needed'. many discoveries. Dreidax (Heidelberg) Enh hijacking #AACR17
12:33pm April 5th 2017 via Hootsuite
Polyak: Looking at gene class dependency, Hahn (Broad) looking at different categories of dependencies of classes beyond mutations #AACR17
12:31pm April 5th 2017 via Hootsuite
Polyak: Theranostics via Bhujwalla at Hopkins - photoimmunotherapy, after single-dose of light to activate agent in mice #AACR17
12:29pm April 5th 2017 via Hootsuite
Polyak: miRNA in circ exosomes - '16 JCI Insight ref https://t.co/jWs519LuUT #AACR17
12:28pm April 5th 2017 via Hootsuite
Polyak: Diehn showing ctDNA av 6mos before clinical progression; sensitivity 'being perfected in the past few years' #AACR17
12:26pm April 5th 2017 via Hootsuite
Polyak: Velculescu showed ctDNA dynamics during immune checkpoint blockade (unpublished, do not post) Primary vs acquired resist #AACR17
Polyak: #AACR17 (For background, I wrote up this work a few years ago https://t.co/WFJVW7U7C7 great to see it applied)
12:25pm April 5th 2017 via Hootsuite
Polyak Lymph node, tumor, blood, looking at CyTOF (Fluidigm). Looking at activation, differentiation #AACR17
12:24pm April 5th 2017 via Hootsuite
Polyak: Shares work from Nick Navins group (unpublished, do not post) very interesting; Dana Pe'er w/ breast cancer immune atlas #AACR17
12:23pm April 5th 2017 via Hootsuite
Polyak: New method of single-cell library prep without preamplification '17 Nature Methods https://t.co/ukE4BfEWkH #AACR17
12:22pm April 5th 2017 via Hootsuite
Polyak: single-cell profiling; non-invasive detection (both liquid biopsy, molecular imaging), CRISPR, 4D chromatin, AI #AACR17
12:20pm April 5th 2017 via Hootsuite
Kornelia Polyak (Dana Farber MA) Advances in technologies (wrap-up / review) #AACR17
12:19pm April 5th 2017 via Hootsuite
Zhang: Searching for novel genome editing tech - due to accumulation of microbial genome data 'unprecedented opps for discovery' #AACR17
11:49am April 5th 2017 via Hootsuite
Zhang: Showing EGFR L858R 'as little as 0.1%', more optimization being done. Affordable, quick, sensitive method. #AACR17
11:48am April 5th 2017 via Hootsuite
Zhang: Shows attomolar detection with C2c2 detection w/fluorescence. Also shows ability to detect ctDNA (37C 2h via RPA) (unpubl) #AACR17
11:47am April 5th 2017 via Hootsuite
Zhang: C2c2 is very stable, can be freeze-dried on paper, for RNA-based viruses. Lentiviral Zika, thermal lysis, RT-RPA w/T7... #AACR17
11:45am April 5th 2017 via Hootsuite
Zhang: C2c2 switches also into nonspecific RNAse state after RNA recognition. 'Collateral RNA' degradation #AACR17
11:41am April 5th 2017 via Hootsuite
Zhang: Natural target is MS2, manipulate in ssRNA MS2 phage genome, clone and determine target site. #AACR17
11:40am April 5th 2017 via Hootsuite
Zhang: '17 rev https://t.co/6ag2aoOf9N 2 DNA-targeting, 1 RNA-targeting. Shows one RNA-target effector C2C2 https://t.co/XYBzO3WAob #AACR17
11:39am April 5th 2017 via Hootsuite
Zhang: Looking for novel CRISPR effectors https://t.co/LB9B3VXGT7 Single-component (simpler) #AACR17
11:37am April 5th 2017 via Hootsuite
Zhang: Did selective antisense KO for MOB3B / EMICERI modules; showed transcription is linked. #AACR17
11:35am April 5th 2017 via Hootsuite
Zhang: ID'd six lncRNA candidates that confer increased drug res in melanoma. Zeroing in on one, TCONS_00015940 (EMICERI) #AACR17
11:32am April 5th 2017 via Hootsuite
Zhang: Most enriched hits - carried DNA-binding motifs. Studying lncRNAs, multiple guides targeting TSS promoter upstream of lncRNAs #AACR17
11:31am April 5th 2017 via Hootsuite
Zhang: Look at BRAF V600E mutant cells, and look at ncDNA element bashing on CUL3 gene - found 7% of sgDNA enriched after drug sel #AACR17
11:29am April 5th 2017 via Hootsuite
Zhang: Non-coding targeting 100kb up and downstream of genes '16 Science https://t.co/OpzNaydJIu #AACR17
11:28am April 5th 2017 via Hootsuite
Zhang: '15 rev of CRISPR https://t.co/ZqmenHC5oT able to do high-throughput. What about non-coding elements? Shows BRAF V600E recurr #AACR17
11:26am April 5th 2017 via Hootsuite
